Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Biochemical and immunologic effects of rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

Tsuda M, Moritoki Y, Lian ZX, Zhang W, Yoshida K, Wakabayashi K, Yang GX, Nakatani T, Vierling J, Lindor K, Gershwin ME, Bowlus CL.

Hepatology. 2012 Feb;55(2):512-21. doi: 10.1002/hep.24748.

PMID:
22006563
2.

B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid.

Myers RP, Swain MG, Lee SS, Shaheen AA, Burak KW.

Am J Gastroenterol. 2013 Jun;108(6):933-41. doi: 10.1038/ajg.2013.51. Epub 2013 May 7.

PMID:
23649186
3.

B cell depletion in treating primary biliary cirrhosis: pros and cons.

Yin YF, Zhang X.

World J Gastroenterol. 2012 Aug 14;18(30):3938-40. doi: 10.3748/wjg.v18.i30.3938.

4.

Mycophenolate mofetil for the treatment of primary biliary cirrhosis in patients with an incomplete response to ursodeoxycholic acid.

Talwalkar JA, Angulo P, Keach JC, Petz JL, Jorgensen RA, Lindor KD.

J Clin Gastroenterol. 2005 Feb;39(2):168-71.

PMID:
15681915
5.

Prognostic factors and long-term effects of ursodeoxycholic acid on liver biochemical parameters in patients with primary biliary cirrhosis. Dutch Multi-Centre PBC Study Group.

van Hoogstraten HJ, Hansen BE, van Buuren HR, ten Kate FJ, van Berge-Henegouwen GP, Schalm SW.

J Hepatol. 1999 Aug;31(2):256-62.

PMID:
10453938
6.

Tumor necrosis factor-alpha and transforming growth factor-beta reflect severity of liver damage in primary biliary cirrhosis.

Neuman M, Angulo P, Malkiewicz I, Jorgensen R, Shear N, Dickson ER, Haber J, Katz G, Lindor K.

J Gastroenterol Hepatol. 2002 Feb;17(2):196-202.

PMID:
11966951
7.

Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid.

Angulo P, Jorgensen RA, Keach JC, Dickson ER, Smith C, Lindor KD.

Hepatology. 2000 Feb;31(2):318-23.

PMID:
10655252
8.

Primary biliary cirrhosis with additional features of autoimmune hepatitis: response to therapy with ursodeoxycholic acid.

Joshi S, Cauch-Dudek K, Wanless IR, Lindor KD, Jorgensen R, Batts K, Heathcote EJ.

Hepatology. 2002 Feb;35(2):409-13.

PMID:
11826416
9.

CXCR3 axis in patients with primary biliary cirrhosis: a possible novel mechanism of the effect of ursodeoxycholic acid.

Manousou P, Kolios G, Drygiannakis I, Koulentaki M, Pyrovolaki K, Voumvouraki A, Notas G, Bourikas L, Papadaki HA, Kouroumalis E.

Clin Exp Immunol. 2013 Apr;172(1):9-15. doi: 10.1111/cei.12032.

10.

Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid.

Stojakovic T, Putz-Bankuti C, Fauler G, Scharnagl H, Wagner M, Stadlbauer V, Gurakuqi G, Stauber RE, März W, Trauner M.

Hepatology. 2007 Sep;46(3):776-84.

PMID:
17668874
11.

Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid.

Kuiper EM, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJ, Haagsma EB, Houben MH, Witteman BJ, van Erpecum KJ, van Buuren HR; Dutch PBC Study Group.

Gastroenterology. 2009 Apr;136(4):1281-7. doi: 10.1053/j.gastro.2009.01.003. Epub 2009 Jan 14.

PMID:
19208346
12.

Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid.

Honda A, Ikegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, Saito Y, Takikawa H, Imawari M, Matsuzaki Y.

Hepatology. 2013 May;57(5):1931-41. doi: 10.1002/hep.26018. Epub 2013 Apr 5.

PMID:
22911624
13.

Serum vitamin D level is associated with disease severity and response to ursodeoxycholic acid in primary biliary cirrhosis.

Guo GY, Shi YQ, Wang L, Ren X, Han ZY, Guo CC, Cui LN, Wang JB, Zhu J, Wang N, Zhang J, Cai Y, Han Y, Zhou XM, Fan DM.

Aliment Pharmacol Ther. 2015 Jul;42(2):221-30. doi: 10.1111/apt.13244. Epub 2015 May 18.

14.

Novel Therapies on Primary Biliary Cirrhosis.

Czul F, Levy C.

Clin Liver Dis. 2016 Feb;20(1):113-30. doi: 10.1016/j.cld.2015.08.006. Review.

PMID:
26593294
15.

Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid.

Hazzan R, Tur-Kaspa R.

J Clin Gastroenterol. 2010 May-Jun;44(5):371-3. doi: 10.1097/MCG.0b013e3181c115b3.

PMID:
19881358
16.

Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

Corpechot C, Abenavoli L, Rabahi N, Chrétien Y, Andréani T, Johanet C, Chazouillères O, Poupon R.

Hepatology. 2008 Sep;48(3):871-7. doi: 10.1002/hep.22428.

PMID:
18752324
17.

Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome.

Corpechot C, Chazouillères O, Poupon R.

J Hepatol. 2011 Dec;55(6):1361-7. doi: 10.1016/j.jhep.2011.02.031. Epub 2011 Apr 13.

PMID:
21703194
18.

The influence of sulindac on patients with primary biliary cirrhosis that responds incompletely to ursodeoxycholic acid: a pilot study.

Leuschner M, Holtmeier J, Ackermann H, Leuschner U.

Eur J Gastroenterol Hepatol. 2002 Dec;14(12):1369-76.

PMID:
12468960
19.

Optimum dose of ursodeoxycholic acid in primary biliary cirrhosis.

Verma A, Jazrawi RP, Ahmed HA, Davis T, Bland JM, Benson M, Orchard RT, Theodossi A, Maxwell JD, Northfield TC.

Eur J Gastroenterol Hepatol. 1999 Oct;11(10):1069-76.

PMID:
10524634
20.

Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study.

Papastergiou V, Tsochatzis EA, Rodriguez-Peralvarez M, Thalassinos E, Pieri G, Manousou P, Germani G, Rigamonti C, Arvaniti V, Karatapanis S, Burroughs AK.

Aliment Pharmacol Ther. 2013 Dec;38(11-12):1354-64. doi: 10.1111/apt.12522. Epub 2013 Oct 5. Erratum in: Aliment Pharmacol Ther. 2014 Apr;39(8):904. Rodriquez-Peralvarez, M [corrected to Rodriguez-Peralvarez, M].

Supplemental Content

Support Center